You are here

Eli Lilly

Boehringer, Lilly diabetes drug Tradjenta succeeds in cardiovascular outcome trial

Pharmaceutical Business Review

Sun, 08/26/18 - 12:00 pm

Boehringer Ingelheim

clinical trials

Court tosses kickbacks case against Eli Lilly but allows plaintiffs another chance

Fierce Pharma

Wed, 08/15/18 - 10:27 pm

Accelerator Life Science Partners Launch Startup With $31 Million Series A

CP Wire

Mon, 08/13/18 - 11:15 am

Pfizer Ventures

AbbVie Ventures

Accelerator Life Science Partners

Magnolia Neurosciences Corporation

Elanco’s IPO Would Free Eli Lilly to Focus on Pharmaceuticals

Xconomy

Fri, 08/3/18 - 11:02 pm

Drugmaker Lilly's Elanco animal health unit files for IPO

Yahoo/Reuters

Thu, 08/2/18 - 11:16 pm

Karuna raises $42M to resurrect abandoned Lilly drug for schizophrenia

Fierce Biotech

Thu, 08/2/18 - 09:56 am

Karuna Pharmaceuticals

Alzheimer's disease

Eli Lilly (LLY) Tops Q2 Earnings and Revenue Estimates

NASDAQ.com

Tue, 07/24/18 - 11:23 am

Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease

Fierce Biotech

Tue, 07/24/18 - 10:32 am

Parkinson's Disease

Drugmaker Lilly plans IPO for part of animal health business

Yahoo/AP

Tue, 07/24/18 - 10:28 am

Anima, Eli Lilly pen $1B-plus biobucks research pact

Fierce Biotech

Mon, 07/23/18 - 09:59 am

translation inhibitors

drug development

Trajenta Meets Primary Endpoint in Cardiovascular Trial

CP Wire

Thu, 07/19/18 - 09:47 am

Boehringer Ingelheim

Trajenta Meets Primary Endpoint in Cardiovascular Trial

Thu, 07/19/18 - 09:47 am

Boehringer Ingelheim

Eli Lilly, Pfizer celebrate a PhIII success for their blockbuster pain drug contender tanezumab — but questions linger

Endpoints

Wed, 07/18/18 - 09:51 am

Lilly Oncology’s strategy? Listen to tough talk from patients—and save data for later

Fierce Pharma

Thu, 07/12/18 - 11:57 am

CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes

CP Wire

Mon, 07/2/18 - 10:02 am

Boehringer Ingelheim

CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes

Mon, 07/2/18 - 09:26 am

Boehringer Ingelheim

Touting PhIII success for arthritis drug Taltz, Eli Lilly chases rival Novartis in heated immunology race

Endpoints

Thu, 06/28/18 - 09:45 am

ankylosing spondylitis

ADA: Lilly's Trulicity bests Novo's Victoza, AZ's Bydureon in real-world study

Fierce Pharma

Mon, 06/25/18 - 09:07 pm

ADA: Lilly, BI's Jardiance cut kidney disease progression in Empa-Reg analysis

Fierce Pharma

Mon, 06/25/18 - 09:06 pm

Boehringer Ingelheim

5 Biggest Blockbuster Diabetes Drugs of the Future

Motley Fool

Sun, 06/24/18 - 10:04 am

Boehringer Ingelheim

Pages